China Biologic Products Holdings, Inc. (CBPO), a public company traded on the NASDAQ, today announced that it acquired 80% equity interest in Tianxinfu Medical Appliance Co., Ltd. from PW Medtech Group Limited, a company listed on the Hong Kong Stock Exchange. TianXinFu is involved in the manufacturing and sale of regenerative medical biomaterial products.
In a public announcement, CBPO stated that “the synergies created by this transaction will further expand our top and bottom line financial performance.” TianXinFu is the largest manufacturer of its core product, artificial dura mater, and together with other surgical consumable products it serves over 1,600 hospitals with a strong professional marketing and sales force in China.
As well-established brands in their respective markets, CBPO will be able to strengthen its core plasma therapeutics businesses by leveraging each other’s existing market presence to cross-sell and offer bundle pricing opportunities; to expand our customer bases by growing into each other’s sales channels, hospitals, and departments.
This acquisition will also enable CBPO to unlock the market potential of its new or upcoming high margin coagulation factor products which have greater synergies with some of TianXinFu’s main products. The combined scale could mean reduced costs, optimized spending, broadened market exposure, and improved bargaining power with distributors, customers, and suppliers.
About China Med Device, LLC (CMD) CMD provides turn-key solution for Western medtech companies with regulatory and commercialization services. CMD helps its clients accelerate China entry and growth by offering: market Intelligence and research; CFDA regulatory services (premarket submission, clinical evaluation, clinical trial design & management, post market compliance and legal representation), and other commercial services. If you have an inquiry or feedback regarding our services please email us at info@ChinaMedDevice.com.